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Abstract
Background: Following the World Health Organization’s (WHO) 2015 guidelines recommending initiation of antiretroviral
therapy (ART) irrespective of CD4 count for all people living with HIV (PLHIV), many countries in sub-Saharan Africa have
adopted this strategy to reach epidemic control. As the number of PLHIV on ART rises, maintenance of viral suppression on
ART for over 90% of PLHIV remains a challenge to government health systems in resource-limited high HIV burden settings.
Non facility-based antiretroviral therapy (ART) delivery for stable HIV+ patients may increase sustainable ART coverage in
resource-limited settings. Within the HPTN 071 (PopART) trial, two models, home-based delivery (HBD) or adherence clubs
(AC), were offered to assess whether they achieved similar viral load suppression (VLS) to standard of care (SoC). In this
paper, we describe the trial design and discuss the methodological issues and challenges.
Methods: A three-arm cluster randomized non-inferiority trial, nested in two urban HPTN 071 trial communities in Zambia,
randomly allocated 104 zones to SoC (35), HBD (35), or AC (34). ART and adherence support were delivered 3-monthly at
home (HBD), adherence clubs (AC), or clinic (SoC). Adult HIV+ patients defined as “stable” on ART were eligible for inclusion.
The primary endpoint was the proportion of PLHIV with virological suppression (≤ 1000 copies HIV RNA/ml) at 12months
(± 3months) after study entry across all three arms. Viral load measurement was done at the routine government
laboratories in accordance with national guidelines, annually. The study was powered to determine if either of the
community-based interventions would yield a viral suppression rate drop compared to SoC of no more than 5% in its
absolute value. Both community-based interventions were delivered by community HIV providers (CHiPs). An additional
qualitative study using observations, interviews with PLHIV, and FGDs with community HIV providers was nested in this
study to complement the quantitative data.
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Discussion: This trial was designed to provide rigorous randomized evidence of safety and efficacy of non-facility-based
delivery of ART for stable PLHIV in high-burden resource-limited settings. This trial will inform policy regarding best practices
and what is needed to strengthen scale-up of differentiated models of ART delivery in resource-limited settings.
Trial registration: ClinicalTrials.gov NCT03025165. Registered on 19 January 2017
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Background
Survival for people living with HIV (PLHIV) has dramat-
ically improved with access to potent safe antiretroviral
therapy (ART) [1]. However, to be effective, this treat-
ment is currently delivered as daily oral tablets that re-
quire lifelong adherence [2]. Failure to adhere to
treatment leads to viral recrudescence, clinical symp-
toms associated with immune dysfunction, increased risk
of HIV transmission, and potential development of drug
resistance [1].
The scaling up of antiretroviral therapy (ART) has
been one of the most remarkable public health achieve-
ments in the last decade [3, 4]. There are an estimated
37 million PLHIV globally of whom 21 million are cur-
rently accessing ART. Sub-Saharan African countries
home to approximately 19.4 million PLHIV have imple-
mented an unprecedented scale up of ART especially in
East and Southern Africa [3]. However, how to deliver
sustainable, affordable ART to all PLHIV is an un-
answered question that challenges global HIV care pro-
grams in high HIV burden limited resource settings.
Maintaining patients on ART requires a robust frame-
work to monitor processes, outcomes, and long-term
impact both at individual and programmatic levels. Re-
tention on ART is a crucial indicator both at individual
and programmatic levels and patient outcomes may be
threatened if ART retention is poor or deteriorating [5–
10]. Adherence to ART is necessary for individual pa-
tient outcomes as well as to reduce the risk of drug re-
sistance from a public health perspective [11, 12]. Many
studies have identified existing fragile health systems, in-
adequate human resources, transportation costs, fre-
quent pharmacy pick-ups, and long waiting times at the
clinic as significant barriers to ART retention in
resource-limited settings [13–18] and without a change
in the current model of ART delivery in resource-
limited settings, lifelong ART for PLHIV may be unsus-
tainable. As treatment coverage increases in the coming
years, it is unlikely that human, financial, and physical
resources will grow in proportion to this increase and
there is therefore an urgent need to develop innovative
models of ART delivery that can be implemented sus-
tainably without compromising the quality of care.
Decentralization of HIV services to community level
may be an important strategy to improve sustainability
of programs [18]. Community models of ART delivery
are one example of decentralizing HIV services from the
health care facilities to the community. These models
have been developed in various resource-limited settings
and hold the promise of improving the continuum of
care by decongesting the clinics and strengthening com-
munity engagement by linking community-based pro-
grams with the health care facilities [1, 19, 20].
Furthermore, the 2015 WHO guidelines [2] have rec-
ommended the provision of ART services in the com-
munity, but there is need for operational guidance and
further evidence for this to happen in practice [1]. This
resulted in the development of the “Differentiated Care”
framework which has been defined as a client-centered
approach that simplifies and adapts HIV services across
the cascade, in ways that serve both the needs of PLHIV
better and reduce unnecessary burdens on health sys-
tems [21].
The purpose of the framework is to provide guidance
on how to address the barriers to treatment access and
retention in care by optimizing models of care and drug
delivery [21, 22] and focuses on stable patients who are
defined as PLHIV adherent to treatment, who have no
opportunistic infections and do not require frequent
clinical consultations. However, this definition varies
across different models dependent on access to re-
sources, such as viral load monitoring [21].
Evidence base of community models of ART
delivery in resource-limited settings
Several studies have assessed the feasibility of commu-
nity models of ART delivery in sub-Saharan Africa
where the facility serves as the referral site, showing fa-
vorable outcomes in relation to retention in care and
viral suppression [23, 24]. While 2 randomized trials
have been conducted in Kenya and Uganda comparing
home-based ART delivery to facility-based care [25–28],
as well as observational studies on different models of
ART delivery [23, 24, 29–33], most of these studies have
been implemented in rural areas where patients live far
from the health care facilities. We want to understand
how such models would work in overcrowded, urban
communities where community cohesion may be more
limited. There is still a lack of evidence about which
model is the most feasible and cost effective or whether
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patient outcomes will be as good as the current standard
quality of care in high prevalence urban resource-limited
settings. Therefore, additional data are required from al-
ternate models of ART delivery that support long-term
retention and virological suppression and evaluate which
is the most feasible to fit into the current health system
and community as well as the most-cost-effective
strategy.
Our trial differs from the previous two trials described
above in several aspects. Firstly, this will be the first
study to rigorously evaluate two different models of
ART delivery, home-based ART delivery and adherence
clubs in a high HIV prevalence resource-limited urban
setting in SSA compared to SoC for ART delivery. Sec-
ondly, this study uses a cluster-randomized trial design
to do a non-inferiority comparison between SoC and
each of the two models of community ART delivery. Fi-
nally, this trial will be able to assess the effect of shifting
patients from routine ART care into the community and
assess patient preferences and satisfaction unlike the tri-
als conducted in Uganda and Kenya [25–28].
We designed a three-arm cluster-randomized non-
inferiority trial comparing two different community
model of ART delivery with the current standard of care
to gather evidence on the impact of these models on pa-
tients’ clinical and virological outcomes, operational
feasibility, acceptability, and cost-effectiveness to guide
policy makers on best models to roll out in the context
of universal treatment. An additional exploratory quali-
tative study was nested in this trial to complement the
quantitative data. The reason for choosing this mixed-
methods approach was to gather robust data to deter-
mine whether delivering ART and support outside the
health care facility by community workers is safe and
feasible and using viral suppression as our primary end-
point. In addition, several underlying social-contextual
and health system factors such as delivering drugs out-
side the health care facility to patient homes or clubs, in-
vasion of privacy, and community-based stigma needed
to be explored. This design enabled us to robustly ex-
plore the safety, efficacy, acceptability, and feasibility of
these models of ART delivery.
This paper looks at several aspects of our study design in-
cluding why we chose a non-inferiority design, cluster versus
individual randomization, as well as anticipated challenges,
advantages, and disadvantages of the study design.
Methods
Study setting
This study was nested within the recently published
HPTN 071 (PopART) trial and full details of this trial
have been described elsewhere [34]. Briefly, HPTN 071
(PopART) was a cluster randomized trial done in 21
communities in Zambia and South Africa to estimate
the effect of a combination HIV prevention package,
which included door-to-door HIV testing services, link-
age to care, immediate ART for HIV-positive individuals,
and promotion of male circumcision for HIV-negative
men, on HIV incidence between 2014 and 2018 [34].
Our nested study was conducted in the catchment popu-
lation of 2 urban primary health care facilities that
served two of the HPTN 071 trial communities in
Lusaka, Zambia. The two sites were purposively selected
for the following reasons:
1) Both communities were randomized to the
intervention arms of the main HPTN 071
(PopART) trial, where community HIV care
providers (CHiPs) were already employed to deliver
the HIV combination prevention package through
annual rounds of household visits throughout the
entire communities.
2) Both communities have a high number of HIV
patients in care (approximately 10,000) with a
critical shortage of staff (0.8 per 1000 population)
(http://www.aho.afro.who.int/profiles_information/
index.php/Zambia:Health_workforce_-_The_
Health_System) and are therefore an ideal setting to
determine if these models of ART delivery benefit
the health care facilities by decongesting the clinics
and making treatment easier to access.
At the time of the study design (in 2016), the two
communities had an HIV prevalence of approximately
20% among adults aged 18–44, and an estimated 70% of
all PLHIV were accessing ART. This trial utilized exist-
ing CHiPs from the HPTN 071 trial to deliver the inter-
ventions. The CHiPs are trained members of the
community, appointed to provide a package of basic ser-
vices at household level, particularly HIV counseling and
testing, screening for tuberculosis and sexually transmit-
ted infections and linking household members for ap-
propriate HIV prevention, treatment, and care services.
The CHiPs work in pairs within allocated zones of the
community (each zone consisting of 450–500 house-
holds), and this provided our study with the unique op-
portunity for them to provide the study intervention
such as adherence support, symptom screening, and dis-
pensation of pre-packed medications, while the CHiP
zones offered a convenient and appropriate unit of
randomization.
Study design
This study was a three-arm cluster-randomized non-
inferiority trial in a cohort of adult HIV+ patients on
treatment in two urban health care facilities. Prior to the
start of the main HPTN 071 (PopART) trial, mapping of
the households and non-residential buildings was done,
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with a census to estimate the total number of adults and
children allowing us to define a population of approxi-
mately 100,000 people per community to be included in
the door-to-door intervention. This “intervention popu-
lation” was then sub-divided into “CHiP zones” with
each zone consisting of around 500 households and
served by a pair of trained CHiPs. An additional qualita-
tive study using observations of home delivery and clubs,
interviews with PLHIV accessing ART via these models
of delivery and group discussions with CHiPs delivering
the intervention was nested within the main trial to
complement the quantitative data.
Randomization
The unit of randomization was a CHiP zone and random
allocation of zones was done prior to recruitment of eli-
gible participants. There were two communities with
104 zones in total: 54 in community 1 and 50 in com-
munity 2. Randomization was performed separately in
the two communities. We restricted the randomization
within each community on average values of key out-
comes measured during the PopART intervention
rounds to ensure balance across the three study arms on
these factors. These were population size, HIV preva-
lence, proportion of PLHIV who attend the local clinic,
and distance to the clinic.
For each community, one million potential permuta-
tions of allocations of zones into three trial arms (A, B,
and C) were generated. Each permutation was assessed
for balance across arms on the five factors, and if they
were not within acceptable limits, then that permutation
was discarded. From those remaining permutations that
were balanced on the five factors, 10,000 were selected
at random and numbered from 0000 to 9999. This pro-
vided 10,000 acceptable random allocations for each
community with the final allocation to be selected from
these at a public randomization ceremony.
We conducted two randomization ceremonies, one for
each community separately on the 11 and 13 April 2017.
In one community, we used a church hall and in the other
community, a school hall. In each of the randomization
ceremonies, we invited the CHiPs (108 and 100 in com-
munities 1 and 2 respectively), 4 CHiP supervisors, 10
members of the PopART intervention team, 5 health care
workers, 4 community advisory board members, 5 health
care staff, and 1 community mobilizer to select the final
allocation of zones to one of the three study arms.
We numbered 10 balls from 0 to 9 and asked 4 individ-
uals from each of the above cadres to pick a ball, record
the number, and put it back in the bag, giving a four-digit
number between 0000 and 9999. This four-digit number
was then used to select a single final allocation from the
10,000 generated earlier, allocating each zone to a trial
arm: A, B, or C. Once this was done, we asked the CHiPs
to take note under which arm their zones were allocated
to and asked them to move towards their allocated arm in
3 separate corners of the room. A verification process was
done by the study team to ensure that CHiPs serving their
zones moved to the correct arm allocation. The next step
included taking 3 sheets of papers, each labeled either
HBD, AC, or SOC, folded, and put in a small box. From
each of the 3 CHiP corners, we asked an individual
(agreed by the CHiP teams) to pick 1 paper from the box.
Once a paper was picked, it was revealed and the model of
delivery was allocated to them. (i.e., if a CHiP from the al-
located arm A picked a paper that was written HBD that
was the model allocated to arm A, etc.).
Study population and eligibility
All stable adult PLHIV (≥ 18 years) residing in the two
urban communities enrolled in HIV care at the two pri-
mary health care facilities were eligible for study inclusion.
Guided by the WHO classification for “stable” patients
[22], we included all patients who were (1) on first-line
therapy for at least 6months, (2) virally suppressed using
national guidelines [HIV RNA ≤ 1000 copies/ml] where
viral load was taken less than 12months prior to enrol-
ment, and (3) had no other health conditions requiring
the attention of a clinician. An additional eligibility criter-
ion for our study included patients living within the study
catchment area and being willing to provide written in-
formed consent to participate in the study.
Study procedures: screening and enrolment
During the enrolment period, the study staff screened all
PLHIV attending the health care facility to determine who
was stable according to the above definition. Stable pa-
tients were then asked whether they resided within the fa-
cility catchment area. Those who reported living in the
catchment area were then met by the community
mobilizer who confirmed their residence using the main
trial intervention map. Having confirmed this, they were
seen by the study nurse who was responsible for introdu-
cing the study to the potential participants and obtaining
written informed consent. All participants were consented
and enrolled before their random allocation was revealed
to them. Participants who were allocated to the interven-
tion arms (home-based delivery and adherence clubs)
were given the choice of the allocated intervention or to
continue receiving care in the clinic (SoC).
Description of study interventions
A. Home-based ART delivery (HBD)
In zones randomized to HBD, a pair of CHiPs visited
the participant in their homes once every 3 months to
provide adherence support, symptom screening, and dis-
pense pre-packed drugs. The participants were required
to visit the clinic once every 6 months (twice in a year)
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for a routine clinical review and laboratory monitoring
as per national guidelines. Table 1 gives a broad over-
view of the HBD model.
B. Adherence clubs (AC)
An adherence club consisted of a group of at least 20–
30 stable PLHIV living within the same CHiPs zone and
enrolled at the community health care facility. Each zone
had one club and club members met once every 3
months at an agreed communal venue where they re-
ceived adherence support, symptom screening, and pre-
packed medications delivered by a CHiP pair. Club
members were required to have 2 clinical visits (every 6
months) in a year for their routine clinical review and la-
boratory monitoring (Table 1).
In both the intervention arms, participants who de-
veloped any symptoms or became ill were referred to
the health facility for further investigations and man-
agement. Participants found to have detectable viral
loads, tuberculosis, and other common conditions
were transitioned to clinic-based care for further
follow-up.
C. Standard of care (SoC)—control arm
Participants living in zones allocated the SoC arm con-
tinued receiving care and ART prescriptions at the
clinic. Currently, standard of care in Zambia includes
patients visiting the clinic once every 3 months for drug
collection and clinical monitoring depending on their
last clinical and laboratory monitoring.
Study hypothesis and rationale
The principal hypothesis is that clinical and virological
outcomes in patients receiving the community-based
interventions (HBD and AC) are non-inferior to those
receiving care in the clinic (SoC) in an urban resource-
limited setting. The rationale for the control arm selec-
tion is that care at the facility is the gold standard for
stable ART patients in Zambia, and the rest of the world.
The non-inferiority design applies to the primary out-
come (proportion of participants who are virally sup-
pressed), and the rationale for this design is that if viral
suppression is found to be no worse in the intervention
arms vs. the control arm, then the intervention will be
preferable to the current standard of care. We set our
non-inferiority margin at 5%, and the two primary com-
parisons will include a test of non-inferiority between
home-based delivery vs. standard of care and adherence
clubs vs. standard of care.
Study endpoints and definitions
The primary endpoint in this trial was the proportion of
patients with virological suppression at 12 months (± 3
months) after study entry across all three study arms.
Viral load measurement used for our primary outcome
was the measurement taken closest in time to 12-month
post enrolment. If no measurement was taken within 90
days before or after this 12-month point, then the pri-
mary outcome was considered to be missing. We used
the routine viral load testing results which according to
the Zambian guidelines is defined as VL RNA ≤ 1000
copies/ml (based on the parameters of any assay per-
formed through routine laboratory monitoring) and con-
ducted at 6 and 12months post ART initiation and
thereafter annually for all stable patients. Secondary end-
points of this trial (assessed at the end of the trial) are as
follows: (1) proportion of patients virally suppressed at
20 and 24months after study entry (as measured by last
VL taken between 20 and 24months after study entry)
and (2) proportion of patients loss-to follow-up (LTFU)
Table 1 Broad overview of the three ART delivery models
Home-based delivery (HBD) Adherence clubs (AC) Standard of care (SoC) Comments
Clients are visited in their
home by the CHiPs
Group of 20–30 clients meet
at an agreed community
venue led by a pair of CHiPs
Clients visit the clinics
as scheduled





ART dispensed 3 months 3 months 3 months














Frequency of clinical monitoring 2 (every 6 months) 2 (every 6 months) 2 (every 6 months)
Process • Symptom screening
• Adherence support
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and died 12months after study entry. LTFU was defined
as having no contact > 90 days after last missed sched-
uled appointment with unknown outcomes after study
entry. Study participants who were transferred out of the
health care facility were not considered LTFU but termi-
nated from the study and other reasons for termination
included death, LTFU, and study withdrawal; (3) propor-
tion of patients retained in the intervention models after
12, 18, and 24months; (4) clinical disease progression 12
and 24 months after study entry; and (5) qualitative re-
search to assess the acceptability and functioning of the
two models of ART delivery based on systematic struc-
tured observations of delivery, in-depth interviews, and
focus group discussions from both the participants and
provider (CHiPs and HCWs) perspectives.
In addition to the above outcomes, the study also
looked at the performance, acceptability and feasibility
of the two models of care using programmatic and rou-
tine health care facility data.
Retention on treatment during the study period was
defined as a documented drug pick up in the last 120
days during the first 12 months after enrolment. Partici-
pants who shifted to another zone with a different inter-
vention or shifted outside the study catchment area but
continued to receive care at the facility were considered
as retained in care. HIV disease progression was defined
as proportion of participants who developed a new or re-
current WHO stage 3 or 4 condition at any given time
after enrolment into study and death was defined at any
point during the study due to any cause.
Additional process data were used to determine model
retention, drug refills, and unscheduled or missed ap-
pointments after enrolment. For retention in the model
of care, participants were considered non-retained if they
transitioned back to standard of care or out of the study
arms for any reason including co-morbidities, LTFU,
death, participant opting out of the intervention, or
withdrawal.
Sample size and study power
Based on the data derived from the first annual round of
the main trial, the number of adults who were known by
the CHiP teams to be HIV+ and on ART at the time of
the most recent follow-up visits averaged approximately
50 individuals per zone, with a harmonic mean of ap-
proximately 36 per zone. Assuming that 80% of such
adults agree to participate in the study and have not
moved out of the community within 12 months after en-
rolment, the number of study participants per zone who
can contribute to the primary endpoint measurement
will have a harmonic mean of approximately 30. Our
study power calculations were done with an assumption
that an average of 30 study participants per zone will
contribute to the primary outcome measurement, and
given there are 104 zones randomized to the 3 arms, this
gives an estimated overall sample size of 3120 partici-
pants. We also assume that among the study participants
in the “standard-of-care” arm, the percentage who are
not virally suppressed 12months after enrolment to the
study is in the range 10–15%. The study was powered to
determine if either of the community-based interven-
tions would yield a viral suppression rate drop compared
to SoC of no more than 5% of its absolute value.
To get the coefficient of variation k, formula k = σ/π.
We assumed the lower end of our mean zone prevalence
(to be conservative) so π = 10%, and we assumed that
there would be approximately a 10% difference in the
prevalence of not being virally suppressed between the
lowest and highest prevalence zones (therefore ranging
from 5 to 15%), equating roughly to a standard deviation
(σ) of 2.5%. So, k = 2.5%/10% = 0.25. We also checked the
power at a more conservative value of 0.3.
If the percentage of participants who are not virally
suppressed at 12 months after study enrolment is 10%
using a two-sided alpha value of 0.05 in the “standard-
of-care” arm, and k = 0.25 or k = 0.3, study power is 93%
and 91% respectively to show that a trial intervention
arm is not inferior to “standard-of care.” The corre-
sponding study power figures are 78% and 74% if the
percentage of participants who are not virally suppressed
at 12 months after study enrolment is 15% in the “stand-
ard-of-care arm.” The power was calculated using the
formula for cluster-randomized non-inferiority trials by
Hayes and Moulton [35]. So, the study, for our expected
sample size, was estimated to have a power of between
74 and 93% under a range of different scenarios
(Table 2). Our estimate of 10% of those not virally sup-
pressed is consistent with research data from these two
communities.
Data collection and tools
This study was implemented by Zambart, a non-
governmental research organization in Zambia recently
having completed the HPTN 071 (PopART) trial and
working closely with the Lusaka District Health Manage-
ment Team and Implementing partners providing tech-
nical support to the health care facilities.
The study was based on prospectively collected routine
data gathered for monitoring and evaluation purposes in
the Zambian ART program. The study’s trained staff are
collecting data from three sources: (1) clinic data where
routine data is being collected at baseline and at every
visit using the national health monitoring and informa-
tion system (HMIS) and patient clinic records, (2) com-
munity Smartcare module specifically designed for the
study where community interactions are recorded in a
hand-held device and later synced with the national
Smartcare database, and (3) study-related forms
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designed specifically for the study that will be used dur-
ing enrolment and throughout the study period to meas-
ure the outcomes and processes of the study objectives.
This will include consent forms, eligibility and enrol-
ment forms, membership registers and attendance
sheets, drug scripts, and study event forms.
To maximize the validity of this information, the study
team worked closely with the health centers to improve
the collection and management of these routine data. A
CONSORT statement checklist has also been to improve
the reporting of our RCT (Additional file 1) [36].
Analysis plan
For the study outcomes, data analysis was conducted as
for a non-inferiority cluster-randomized trial following
the methods outlined by Hayes and Moulton [35]. We
estimated the prevalence in each zone within each arm.
The mean of the zone-specific values was then calcu-
lated for each arm along with its corresponding standard
error and confidence interval (CI). Our non-inferiority
margin was set at 5%. We then compared the control
arm with each of the intervention arms using a one-
sample t test to assess the evidence as to whether the
mean difference between the control and intervention
arms is less than 5%. If the upper limit of the 95% confi-
dence interval (CI) for the difference is less than 5%,
then we accept the intervention as being non-inferior.
The primary analysis was unadjusted.
For our primary analysis, which is viral suppression at
12 months, we used intention to treat (ITT) analysis.
Since participants in the intervention arm were offered
the option to remain in care at the clinic, any who did
so were included in the intervention model they were al-
located to even though they did not select the allocated
model of ART delivery. However, a potential concern
with an ITT analysis is if the uptake of the alternative
methods is low, or if participants move between study
zones or arms resulting in a change to their model of de-
livery, then the intervention arms become similar to the
SoC arm and we may bias the results towards equiva-
lence. So, in addition to the ITT analysis, we performed
a per-protocol analysis (PPA) comparing the outcomes
in those who received SoC (i.e., participants who were
allocated to the SoC arm and those from the
intervention arms who chose to receive SoC) with those
that received HBD/AC. This would help in interpreting
the overall result and should be able to detect if there is,
e.g., a much worse outcome in those opting for home
delivery. We used PPA as a supportive analysis for the
non-inferiority assessment. We also adjusted for poten-
tial confounding in the secondary analysis as the partici-
pants may no longer be balanced, as those who choose
an alternative model may be different from those who
do not, in some ways.
If a participant moved from an intervention zone to
another zone which did not offer the intervention (or of-
fered a different intervention) and therefore reverted to
SoC, we decided to include them in the analysis in their
original arm as per the principle of ITT. A potential dis-
advantage of this choice is that by including these indi-
viduals, we are making the intervention arm more
similar to the SoC arm and therefore in a non-inferiority
design this is less conservative. However, mobility be-
tween zones was only tracked in the two intervention
arms, so if we chose to exclude individuals who we knew
had moved zones, we would be removing more mobile
individuals from the intervention arms but not from the
SoC arm, and assuming that more mobile individuals are
at greater risk of viral rebound then excluding those in-
dividuals would be less conservative as it could make the
intervention arms look better. Weighing up these two
options, it was thought that the latter issue introduced a
greater risk of bias so the primary analysis would include
those participants (while a sensitivity analysis excluding
them would also be performed).
During the study period and towards the end of the
study (2 months before the end of the intervention), a
team of social scientists collected qualitative data from
the two study sites. To ensure fair representation of the
study sites, purposive sampling was used to select
PLHIV from different age and gender groups as well as
different areas of residence and socio-economic status.
For staff, CHiPs delivering care through the two models
were also selected to participate. Audio-recorded in-
depth interviews (n = 24) were used to collect data from
PLHIV and FGDs (n = 2) were used to collect data from
CHiPs. Data were then triangulated methodically by lon-
gitudinal observations of delivery of the two models (n =
Table 2 Study power showing community ART provision is not inferior to standard-of-care, in terms of viral suppression 12 months
after either enrolling into community ART or continuing with standard-of-care at the clinic
Standard of care, % not virally suppressed








10 5 0.25 30 93
15 5 0.25 30 78
10 5 0.30 30 91
15 5 0.30 30 74
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18). All audio-recorded IDIs and FGDs were then tran-
scribed, and notes taken during observations expanded
in office 2016 and analyzed using Atlas.ti 7.
Ethical considerations
Approval
The study was granted ethical clearance from in-country
authorities [University of Zambia Biomedical Research
Ethics Committee (UNZABREC)], National Health Re-
search Authority [NHRA], and the London School of
Hygiene and Tropical Medicine ethics committee. The
protocol had also been through regulatory review and ap-
proved by Division of AIDS (DAIDS) at NIH, who granted
us permission to carry out this study as an ancillary study
to the main trial and registered at ClinicalTrials.gov.
Consent
Written informed consent was obtained from all eligible
participants and an information sheet about the study
was provided to all participants by the research staff.
Having signed the consent form, the research nurse then
informed the participant which intervention they had
been allocated to or whether they would continue to re-
ceive care at the clinic. Participants allocated to one of
the two intervention arms were offered a choice of
accepting the intervention model or to continue receiv-
ing care at the clinic. Participants who chose the inter-
vention models could opt to receive care at the clinic at
any point during the study period.
Participant safety and monitoring
Throughout the study, for all those participants who
were receiving the interventions, study staff and CHiPs
continuously assessed and monitored participant safety
and ensured that participant confidentiality was main-
tained. Patients in the intervention arms who had symp-
toms requiring a clinician’s attention were referred to
the research nurse at the clinic and those who were not
present during the home or club visit were followed up
by the CHiPs to determine if they did come to the clinic
to pick up their drugs. The study also anticipated social
harms and stigma as these could occur as a result of tak-
ing part in the study and participants might be treated
unfairly or could have problems being accepted by their
families or community members. Although such effects
were expected to be minimal, the study staff and the
CHiP teams monitored these closely throughout the
duration of the study.
Study implementation and challenges
Randomization
Randomization was conducted prior to the start of the
study where statisticians provided 10,000 possible ran-
domized allocations that met the restriction criteria, and
a public randomization ceremony was held in both com-
munities to select the final allocation of zones to the
study arms. A total of 104 CHiP zones across both com-
munities were randomized (35:35:34) to one of the three
arms: (1) continue collecting ART at the clinic standard
of care (SoC), (2) a choice of home-based ART delivery
(HBD) or remaining in clinic-based care, or (3) a choice
of being in an adherence club (AC) or remaining in
clinic-based care (Fig. 1).
Recruitment
All potential participants who fulfilled the definition of
“stable patients on ART” in accordance with the pre-
defined eligibility criteria during the screening process
were sent to the research nurse for eligibility screening.
Eligible participants who were able to demonstrate un-
derstanding of the study were asked to provide written
informed consent. Having consented to the study, the
participant’s residential address was located using the
intervention map to identify the zone they were living
in. Participants were then informed of the intervention
arm they were allocated to. Participants allocated to the
intervention arms had the option to take up the offer or
continue receiving care at the clinic whereas those allo-
cated to the control arm had no option but to continue
care at the clinic. A total of 2503 stable patients were
identified across the two communities between May and
December 2017 who were eligible for inclusion in the
trial and of these 2493 (99.6%) consented to participate
and 10 (0.4%) declined consent (Fig. 2). Of the partici-
pants who consented, the majority were female (n =
1761, 71%). Median age of participants was 40 years
(IQR 33–47) and the median years being on ART was 4
years (IQR 2–7).
Challenges with recruitment
A total of approximately 9962 patients were screened
across both communities between May and December
2017. We experienced a number of challenges during
the screening process. First, most participants did not
have a viral load test taken or had not received their re-
sults in the preceding 12months as recorded in their
clinical records at the time of screening. Thus, the study
team had to send a patient for VL testing. Viral load re-
sults from the laboratory took between 1 and 3months
and study staff had to wait for another 1–3 months to
determine eligibility. Secondly, some participants were
not physically present at the clinic as they had their
treatment supporters or “buddies” come and collect their
drugs. The study team had asked the treatment sup-
porters to inform the patient to come the following
week or during their next scheduled visit. Thirdly,
some patients were on treatment for less than 6
months and could only be enrolled in their
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consecutive visits if treatment duration was more than
6 months and they had a 6-month undetectable viral
load result. Other reasons included having a detectable
viral load, being on 2nd line treatment or having
missed more than 2 clinical or drug pick up visit in
the last 12 months.
Of the total number of patients who were considered
stable, we further excluded a large number of patients as
they were living either outside the study catchment area
or in a community where the interventions were not
offered.
Discussion
This was one of the first studies conducted in an urban
resource-limited high HIV burden setting that rigorously
compared clinical and virological outcomes of patients
Fig. 1 Randomization scheme
Fig. 2 Recruitment and enrolment flow chart
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participating in community models of ART delivery to
current facility-based ART delivery as standard of care.
In this paper, we present and describe the rationale for
conducting a cluster-randomized non-inferiority trial to
compare patient outcomes in community models of
ART delivery among stable HIV+ patients in Zambia.
Most randomized trials are superiority trials and assess
whether a new treatment is more efficacious than a pla-
cebo or current standard of care [37], whereas non-
inferiority trials are intended to test whether a new treat-
ment is no worse than a standard treatment by more
than a specified margin and such trials have gained
much attention in the last decade [37]. For our study,
the rationale is to provide evidence on patient outcomes,
acceptability, and feasibility of different models of ART
delivery in resource-limited settings and whether these
are novel strategies to scale up in the context of univer-
sal treatment in an effort to minimize the barriers to
accessing care and treatment as we move towards the
UNAIDS target of ending the epidemic by 2030. We
used this design because in resource-limited settings,
such as in Zambia, community models of ART delivery
are being identified as a way of expanding treatment and
the government through the National AIDS Council has
engaged several in-country partners and researchers to
pilot different models of ART delivery in order to generate
information required to inform model standardization at
national level for wider roll-out. Community models of
ART delivery are likely to become part of standard of care
if it does not negatively affect patient clinical outcomes as
compared to the gold-standard which is the current stand-
ard of care.
The choice of this non-inferiority design was to test
that clinical outcomes of patients under different models
of ART delivery are not significantly inferior to the
current standard of care, thereby showing that in
resource-limited settings, these models of ART delivery
can be considered as standard of care. Introducing these
models of ART delivery as standard of care may poten-
tially have long-term benefits such as decongesting the
overburdened clinics to allow health care workers to
concentrate on more complex patients, reduce patients’
financial and transport burdens of having to attend the
clinics frequently for their drug pick-ups as well as im-
prove community engagement and support towards HIV
care and treatment. In contrast, a superiority trial design
would not be feasible in resource-limited settings as it
will require a lot of resources and would require health
care workers to provide an intervention that shows su-
periority over the current gold standard of care.
This trial used cluster rather than individual
randomization following in the footsteps of several large
and ambitious trials of interventions against HIV and
other infectious diseases in low and middle income
countries that have helped guide health policy over the
last decade or more [38]. These type of trials are used
increasingly where delivery of intervention is at a group
level and outcomes measured at patient level [39]. The
decision to design a cluster randomized over an indi-
vidually randomized trial for our study was that (1) it
was ideally suited to study interventions that in practice
had to be delivered at cluster (in this case, a zone) level,
(2) it avoids the risk of contamination where participants
from the control arm might receive some components
of the intervention, and (3) this trial design was best de-
signed to capture the effects of these interventions at
community level.
In addition to the above, the communities were
already divided into zones (clusters) by the main trial
and it was logistically more feasible to train CHIPs on
the particular interventions they would deliver rather
than train them on all the interventions. It was also eas-
ier to control and monitor the interventions unlike indi-
vidual randomization where it would have been difficult
to deliver and monitor the interventions. In the case of
adherence clubs, a club could be set up within each AC
zone, meaning the clubs are close to participants’ homes,
but if the trial was individually randomized, participants
in the AC arm would be more geographically disparate
and therefore in some cases far away from their allo-
cated club, which could result in patients opting out of
interventions.
This study has a robust design in being the first cluster
randomized trial to explore outcomes of virological sup-
pression, retention, feasibility, and acceptability of differ-
ent ART delivery models and comparing it to the
standard of care in a high prevalence urban setting and
therefore provide us with evidence that could be
generalizable to other sub-Saharan African settings and
also inform policy regarding the best models to scale up.
In addition to the above outcomes, this study also pro-
vided participants with a choice of continuing care at
the clinic or receiving a community-based intervention
and considered participant’s preferences towards the dif-
ferent models of ART delivery.
Despite the study strengths, non-inferiority trials have
several challenges and limitations. As discussed in the
analysis plan above, one of the challenges will be how
best to analyze the data and whether to use ITT or PPA
as we will have to deal with movements of participants
between zones resulting in a change to their model of
ART delivery. Assuming that both intervention arms are
non-inferior to the standard of care arm, it would be de-
sirable to determine whether one intervention arm is su-
perior to the other (home delivery vs. adherence clubs).
Although the study will not necessarily be powered to
test this, other indexes on model uptake and retention,
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drop-out rates, and cost effectiveness can still be used to
inform policy makers on model preferences.
Other limitations include the possibility of selection
bias, where patients in the control arm may hear about
the two models of delivery and may move from one zone
to another which is providing the intervention. To avoid
this, we asked patients at enrolment where they actually
live and confirmed this with CHiPs who worked in those
zones. Uniformity of implementing the interventions
may change over time due to external factors such as
bad weather and political climate. Another limitation
was the substantial mobility and in-migration of partici-
pants within these urban communities as observed in
the main trial [40, 41] thus requiring consideration of
how to handle patients who relocate from one zone to
another zone or community. There is also a source of
bias as to who consents and who does not and those
who take part in the study may not be representative of
the general population. Another factor to be considered
is that the study power might leave us underpowered if
more than half of the adults in each zone opt to with-
draw and return to standard of care as a result of stigma
and disclosure. Other challenges included using routine
data for measuring outcomes such as viral load results
as most of these results were either missing or yet to be
updated in the facility health care database and patient
clinical records. To address this challenge, the study
team worked closely with the clinic staff and laboratory
staff to have viral load results entered in the clinic data-
base and patient files.
As we move towards scale up of ART services to meet
the UNAIDS target, there is need to provide evidence on
the feasibility, outcomes, and cost effectiveness of differ-
entiated care models and how best they can be com-
bined alongside routine ART services. This trial will
provide important data informing policy regarding best
practices and what is needed to strengthen the scale up
of differentiated care.
Trial status
Enrolment into the trial commenced on 2 May 2017 and
completed recruitment on 15 December 2017. The study
recruited 2493 patients across the two urban communi-
ties and follow-up of participants ended in April 2019.
The main trial outcome will be reported in 2020.
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